Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110


Centrosome duplication is critical for cell division, and genome instability can result if duplication is not restricted to a single round per cell cycle. Centrosome duplication is controlled in part by CP110, a centriolar protein that positively regulates centriole duplication while restricting centriole elongation and ciliogenesis. Maintenance of normal CP110 levels is essential, as excessive CP110 drives centrosome over-duplication and suppresses ciliogenesis, whereas its depletion inhibits centriole amplification and leads to highly elongated centrioles and aberrant assembly of cilia in growing cells1,2. CP110 levels are tightly controlled, partly through ubiquitination by the ubiquitin ligase complex SCFcyclin F during G2 and M phases of the cell cycle3. Here, using human cells, we report a new mechanism for the regulation of centrosome duplication that requires USP33, a deubiquitinating enzyme that is able to regulate CP110 levels. USP33 interacts with CP110 and localizes to centrioles primarily in S and G2/M phases, the periods during which centrioles duplicate and elongate. USP33 potently and specifically deubiquitinates CP110, but not other cyclin-F substrates. USP33 activity antagonizes SCFcyclin F-mediated ubiquitination and promotes the generation of supernumerary centriolar foci, whereas ablation of USP33 destabilizes CP110 and thereby inhibits centrosome amplification and mitotic defects. To our knowledge, we have identified the first centriolar deubiquitinating enzyme whose expression regulates centrosome homeostasis by countering cyclin-F-mediated destruction of a key substrate. Our results point towards potential therapeutic strategies for inhibiting tumorigenesis associated with centrosome amplification.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Identification of USP33 as a CP110-associated protein.
Figure 2: USP33 localizes to centrosomes primarily during S and G2/M phases of the cell cycle.
Figure 3: Recruitment of USP33 leads to deubiquitination and stabilization of CP110.
Figure 4: Depletion of USP33 inhibits centrosome amplification and antagonizes cyclin-F function.


  1. 1

    Chen, Z., Indjeian, V. B., McManus, M., Wang, L. & Dynlacht, B. D. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev. Cell 3, 339–350 (2002)

    CAS  Article  Google Scholar 

  2. 2

    Spektor, A., Tsang, W. Y., Khoo, D. & Dynlacht, B. D. Cep97 and CP110 suppress a cilia assembly program. Cell 130, 678–690 (2007)

    CAS  Article  Google Scholar 

  3. 3

    D’Angiolella, V. et al. SCFCyclin F controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 466, 138–142 (2010)

    ADS  Article  Google Scholar 

  4. 4

    Li, J. et al. Neurl4, a novel daughter centriole protein, prevents formation of ectopic microtubule organizing centres. EMBO Rep. 13, 547–553 (2012)

    CAS  Article  Google Scholar 

  5. 5

    Sowa, M. E., Bennett, E. J., Gygi, S. P. & Harper, J. W. Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389–403 (2009)

    CAS  Article  Google Scholar 

  6. 6

    Li, Z. et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 277, 4656–4662 (2002)

    CAS  Article  Google Scholar 

  7. 7

    Li, Z. et al. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressor. Biochem. Biophys. Res. Commun. 294, 700–709 (2002)

    CAS  Article  Google Scholar 

  8. 8

    Curcio-Morelli, C. et al. Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. J. Clin. Invest. 112, 189–196 (2003)

    CAS  Article  Google Scholar 

  9. 9

    Thorne, C., Eccles, R. L., Coulson, J. M., Urbe, S. & Clague, M. J. Isoform-specific localization of the deubiquitinase USP33 to the Golgi apparatus. Traffic 12, 1563–1574 (2011)

    CAS  Article  Google Scholar 

  10. 10

    D’Angiolella, V. et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149, 1023–1034 (2012)

    Article  Google Scholar 

  11. 11

    Berthouze, M., Venkataramanan, V., Li, Y. & Shenoy, S. K. The deubiquitinases USP33 and USP20 coordinate β2 adrenergic receptor recycling and resensitization. EMBO J. 28, 1684–1696 (2009)

    CAS  Article  Google Scholar 

  12. 12

    Chan, J. Y. A clinical overview of centrosome amplification in human cancers. Int. J. Biol. Sci. 7, 1122–1144 (2011)

    CAS  Article  Google Scholar 

  13. 13

    Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278–282 (2009)

    CAS  ADS  Article  Google Scholar 

  14. 14

    Buchholz, M. et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24, 6626–6636 (2005)

    CAS  Article  Google Scholar 

  15. 15

    Badea, L., Herlea, V., Dima, S. O., Dumitrascu, T. & Popescu, I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55, 2016–2027 (2008)

    CAS  PubMed  Google Scholar 

  16. 16

    Sato, N. et al. Centrosome abnormalities in pancreatic ductal carcinoma. Clin. Cancer Res. 5, 963–970 (1999)

    CAS  PubMed  Google Scholar 

  17. 17

    Sato, N. et al. Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet. Cytogenet. 126, 13–19 (2001)

    CAS  Article  Google Scholar 

  18. 18

    Shono, M. et al. Stepwise progression of centrosome defects associated with local tumor growth and metastatic process of human pancreatic carcinoma cells transplanted orthotopically into nude mice. Lab. Invest. 81, 945–952 (2001)

    CAS  Article  Google Scholar 

  19. 19

    Cohen, P. & Tcherpakov, M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143, 686–693 (2010)

    CAS  Article  Google Scholar 

  20. 20

    Sippl, W., Collura, V. & Colland, F. Ubiquitin-specific proteases as cancer drug targets. Future Oncol. 7, 619–632 (2011)

    CAS  Article  Google Scholar 

  21. 21

    Tansey, W. P. Detection of ubiquitylated proteins in mammalian cells. Cold Spring Harb. Protoc.. (2006)

  22. 22

    Sabbaghian, M. S. et al. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Res. 30, 2911–2917 (2010)

    PubMed  Google Scholar 

  23. 23

    Seeley, E. S., Carriere, C., Goetze, T., Longnecker, D. S. & Korc, M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res. 69, 422–430 (2009)

    CAS  Article  Google Scholar 

Download references


We thank C. Hajdu, G. Miller, L. Chiriboga, H. Court, C. Zambirinis, E. Bekes, L. Taylor, S. Krauter, M. Philips and D. Bar-Sagi for help with staining and analysis of pancreatic cancer samples. We thank F. Liang, Y. Deng, C. Petzold and K. Dancel for help with correlative electron microscopy. We thank J. Jastrab and S. Vijayakumar for initial experiments pertaining to the USP20–CP110 interaction. We thank J. Pollack for providing pancreatic cell lines. We thank G. Wu, S. Shenoy, R. Baer and T. Huang for providing plasmids. We thank members of the Dynlacht laboratory and T. Huang for advice. B.D.D. was supported by National Institutes of Health grant 5R01HD069647-02 and March of Dimes grant FY11-432. M.P. is an Investigator with the Howard Hughes Medical Institute.

Author information




J.L., V.D’A., S.K., T.K., E.I.C., M.P. and B.D.D. performed all biochemical experiments and analyses of deubiquitination and centrosome phenotypes. E.S.S., W.F. and J.L. performed pancreatic tissue studies. J. L. and B.D.D. wrote the manuscript. B.D.D. coordinated the study and oversaw all experiments. All authors discussed the results and commented on and assisted in revising the manuscript.

Corresponding author

Correspondence to Brian David Dynlacht.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-9. (PDF 2557 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Li, J., D’Angiolella, V., Seeley, E. et al. USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110. Nature 495, 255–259 (2013).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links